Biopharma SHAKTI commits Rs. 10,000 crore to scale biologics manufacturing, translational research, and supply chains over five years, a strategic bet on biosimilars, advanced therapies, and domestic capacity. The fund aims to foster industry-academia incubators, incentives for advanced production, and a stronger export orientation. If executed, the scheme could reduce import dependence, lower therapy costs, and attract global investment into India’s next-generation drug industry. This measure requires clear timelines and state-level coordination.
Trending
- Why Entrepreneurs Struggle With Dating (And How to Fix It)
- Herbs of Gold and CARiNG Pharmacy inspire women to put their well-being first in a new campaign
- Social Security July 2026 Payment Schedule: When Beneficiaries…
- Four states just made it easier to build wildlife crossings
- 9 eating habits that could be hurting your brain
- 10 retirement myths that can hurt you in the long run
- Shell’s New Concept EV Designed to Charge in Under 10 Minutes and Run at 6 miles per kWh
- How Emotional Intelligence Is Transforming Senior Care
Monday, July 6
